Nanobiotix downgraded to Neutral from Buy at UBS

UBS downgraded Nanobiotix (NBTX) to Neutral from Buy with a price target of $3.50, down from $12, as a new analyst assumed coverage of the stock. The next major catalyst is more than 12 months away and the firm sees a near-term financing overhang limiting potential upside, the analyst tells investors.